key: cord-0684218-vymc4rpg
authors: Bostan, Ecem; Zaid, Fethi; Karaduman, Aysen; Dogan, Sibel; Gulseren, Duygu; Yalici‐Armagan, Basak; Akdogan, Neslihan; Ersoy‐Evans, Sibel; Elcin, Gonca
title: The effect of COVID‐19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross‐sectional, comparative study
date: 2021-10-02
journal: J Cosmet Dermatol
DOI: 10.1111/jocd.14484
sha: 2d0ef95f9553e1bb8cdf5f62c74701bc36a01c5e
doc_id: 684218
cord_uid: vymc4rpg

INTRODUCTION: Chronic spontaneous urticaria (CSU) is defined as recurrent attacks of urticaria present for more than six weeks. The monoclonal anti‐immunoglobulin E antibody, omalizumab, was approved for the treatment of CSU in patients who remain refractory to H1‐antihistamines. Biologic agents are shown not to increase the risk of COVID‐19 infection in different studies. OBJECTIVE: In the present study, we aimed to determine the prevalance of COVID‐19 infection in relation to the age, gender, presence of other comorbidities, and treatment given for CSU. METHODS: We conducted a descriptive cross‐sectional study of 233 patients diagnosed with CSU in a tertiary referral hospital. Demographical data, treatment given for CSU, the presence of COVID‐19‐related symptoms, history of close contact to a person with COVID‐19 and COVID‐19 real‐time polymerase chain reaction (RT‐PCR) results were determined via a telephone survey and checked from medical data records. RESULTS: One hundred sixty patients were female; whereas 73 were male. The mean age was 44.76. Out of 233 patients with chronic urticaria, 125 had symptoms related to COVID‐19 infection. RT‐PCR testing for COVID‐19 was performed in 156 patients. Of 156 patients with COVID‐19 RT‐PCR test, RT‐PCR result was positive in 15 cases. CONCLUSIONS: No statistically significant relationship was found between COVID‐19 RT‐PCR positivity and the type of treatment administered for chronic urticaria when the patients are divided into omalizumab ± oral antihistamines and only oral antihistamines treatment groups (p = 0.150). Omalizumab seems to be safe in the era of COVID‐19.

Chronic spontaneous urticaria (CSU) is a chronic, most commonly idiopathic skin disorder characterized by repetitive episodes of wheal, angioedema, or both present for >6 weeks. 1 Since CSU is mainly characterized by intensive pruritus and may be associated with systemic symptoms such as fever, malaise, joint pain, wheezing and sleep problems, the disease has a great impact on the life quality and daily functioning of the patients. 2 The vasodilatation, inflammatory cell infiltration, increased vascular permeability, erythema, and edema triggered by mast cell-related mediators including histamine, various cytokines, and platelet-activating factor play the substantial role in the etiopathogenesis of CSU. 1 Autoimmune diseases, chronic infectious diseases, functional autoantibodies, and immune dysfunction have all been implicated in the development of chronic urticaria. 1, 3 However, most cases of CSU are shown to remain idiopathic even after long periods of follow-up. 3 Second-generation H1-antihistamines are the first-line treatment of the CSU; up-dosing of second-generation H1-antihistamines up to fourfold are recommended for the patients who remain unresponsive to standard, onefold dose of H1-antihistamines. 1 When there is no improvement with fourfold dose increase, omalizumab is recommended as add-on therapy. 1 Omalizumab is a humanized monoclonal anti-immunoglobulin (Ig) E antibody which selectively targets free human Ig E. 4 Even though approved primarily for the treatmentresistant allergic asthma, it is shown to be efficacious in CSU cases 5 which are unresponsive to the first-line H1-antihistamines and also licensed for CSU in 2014. 6 Omalizumab is shown to exert its effect on CSU by lowering IgE levels, downregulate IgE receptors, decrease the activity of mast cells and IgG autoantibodies which are directed against high-affinity IgE receptors (FcεRI). 7 The safety of biologic agents used for diverse dermatological indications, such as psoriasis, CSU, hidradenitis suppurativa, and atopic dermatitis, is one of the most frequently investigated issues during the COVID-19 pandemic. It is suggested to continue the ongoing therapy with biologic drugs unless COVID-19-related symptoms are reported by the patients. 8 If patients present with symptoms suggestive of COVID-19 such as high fever, dry cough, myalgia, malaise, olfactory, and/or gustatory dysfunction; it is adviced to suspend the biologic drugs immediately. 8, 9 Maintaining physical distancing, using protective equipment, practicing good hygiene, following the rules for isolation and quarantine are strongly recommended for patients using immunosuppressive or immunomodulatory drugs. 8 Omalizumab is shown to reduce the duration of human rhinovirus infection and viral spread thereby decreasing the frequency of systemic complications. 10 Furthermore, omalizumab is shown to enhance the antiviral activity of plasmacytoid dendritic cells by inducing the production of interferon-alpha. 11 In the present study, we aimed to determine the prevalence of COVID-19-related symptoms and COVID-19 real-time polymerase chain reaction (RT-PCR) positivity among CSU patients in relation to the age, gender, disease (CSU) duration, treatment duration, kind of treatment given for CSU. Thus, we tried to determine if omalizumab confers risk for COVID-19 infection compared to the traditional oral antihistamine therapy.

The present study was a comparative, cross-sectional study which involved 233 patients with CSU followed up in our dermatology outpatient clinic. Ethics committee approval was obtained for the study (the date, project number, decision number: 4.5.2021, GO were determined via a telephone survey and also checked from the electronic medical data records. Oral informed consent was taken from all participants before the start of the questionnaire. Only patients who were receiving active-continuous treatment for CSU during the COVID-19 pandemic, were included in the study. 

A total of 233 patients diagnosed with chronic urticaria, were in- Table 1 .

Three (1.3%) patients had history of ovarian cancer, acute lymphoblastic leukemia, and duodenal cancer, respectively, which were all cured currently. Twenty-three (9.9%) had respiratory disease most commonly being asthma, allergic rhinitis whereas 42 (18%) had cardiovascular disease most frequently being coronary artery disease, heart failure, and hypertension. Endocrine disorders, such as diabetes mellitus, autoimmune thyroiditis, and hyperlipidemia, were present in 40 There was no statistically significant relationship between gender vs COVID-19 RT-PCR positivity (p = 0.109) and between age and COVID-19 RT-PCR positivity (p = 0.133) ( Table 2) . No statistically significant relationship was found COVID-19 RT-PCR positivity and the type of treatment administered for chronic urticaria when the patients are divided into omalizumab, omalizumab along with oral antihistamines and only oral antihistamines groups (p = 0.150) ( Table 3 ). There was no statistically significant relationship between COVID-19 RT-PCR results and the presence of previous malignancy, respiratory diseases, cardiovascular diseases, endocrine disorders, and rheumatologic disorders (p > 0.05). We found a statistically significant relationship between COVID-19 RT-PCR results and the mean duration of chronic urticaria treatment (p = 0.020) ( Table 4 ).

The patients with negative RT-PCR results had a higher mean duration of treatment compared to the ones with positive RT-PCR results. We found no statistically significant relationship between the presence of COVID-19 symptoms and the mean age (p = 0.108), the gender (p = 0.422) and the type of treatment given for chronic urticaria (p = 0.802). Additionally, there was no statistically significant relationship between the presence of COVID-19 symptoms and the presence of previous malignancy, respiratory diseases, cardiovascular diseases, and endocrine disorders (p > 0.05). However, statistically significant relationship was found between the presence of COVID-19 symptoms and having a rheumatologic disorder (p = 0.026). The patients with a history of rheumatologic disorder were shown to present with COVID-19 symptoms at a significantly lower rate compared to the ones with no rheumatologic disorders.

Of note, two patients with RA were having oral methylprednisolone and leflunomide; one patient with SLE was receiving hydroxychloroquine, one case with Sjögren's syndrome and one case with FMF were using colchicine, two patients with a diagnosis of OA, were receiving non-steroidal anti-inflammatory drugs whereas one patient with AS was undergoing adalimumab treatment concurrently.

No other patients in the whole group were receiving any other immunomodulatory or immunosuppressive treatment simultaneously.

As expected, there seems to be a statistically significant relationship between the presence of COVID-19 symptoms and COVID-19

RT-PCR positivity (p = 0.003) whereas a statistically significant relationship was also found between the history of close contact to someone with a confirmed COVID-19 and COVID-19 RT-PCR positivity (p = 0.006) ( Table 5) . There was no statistically significant relationship between the mean age vs COVID-19 RT-PCR results (p = 0.133)*and the gender vs COVID-19 RT-PCR results (p = 0.109)**.

Only omalizumab n (%)

Only oral antihistamines n (%)

Positive 0 Maximum 300 120 300

The patients with negative RT-PCR results have a higher mean duration of treatment compared to the ones with positive RT-PCR results (p = 0.020). No statistically significant relationship was found between COVID-19 RT-PCR results and the mean duration of chronic urticaria disease (p = 0.254). 16 On the other hand, some biologics such as TNF-alpha inhibitors are associated with moderate to severe respiratory tract infections. 17

The anti-IgE humanized antibody, omalizumab, is being widely used on-label for the treatment of severe allergic asthma, and CSU.

Patients unresponsive to the first-line treatment with oral histamines up to fourfold are recommended to have 300 mg subcutaneous omalizumab every 4 weeks even though the licensed doses may vary between different countries. 1 However, the dose may be increased up to 450 or 600 mg in recalcitrant cases or partially responsive cases to the standard dose regimen. 18 Omalizumab has been shown to greatly decrease the nasal mucosal inflammation, improve nasal respiratory functions in patients with chronic rhinosinusitis. 19 The mechanisms of action which are associated with its utility in various allergic, hyperinflammatory diseases, are not only limited to binding free IgE and preventing the activation of FcεRI via its interaction with IgE. 7 Omalizumab is also shown to augment antiviral responses via several ways. 20 Firstly, plasmacytoid dendritic cells are shown to express high levels of FcεRI, the binding of specific antigens to these receptors results in the inhibition of interferon-alpha secretion which is crucial to initiate the immunity against viruses. 11 In conclusion, we would like to highlight that omalizumab treatment does not seem to increase the risk for COVID-19 infection and could be safely in patients with CSU, compatible with the data in the literature. In patients with a confirmed diagnosis of COVID-19, omalizumab should be suspended until the infection is completely over. Our study has some limitations since no control group was present and only CSU patients treated in our center were included.

Prospective, randomized controlled studies are needed to further support our findings.

The authors declare that there is no conflict of interest.

Ethics committee approval was obtained.

Approved by the local ethics committee with the date, the project number, the decision number: 4.5.2021, GO 21/604, 2021/10-23. 

The data that support the findings of this study are available from the corresponding author, [Ecem Bostan], upon reasonable request.

Ecem Bostan https://orcid.org/0000-0002-8296-4836

Neslihan Akdogan https://orcid.org/0000-0002-1137-5399

The EAACI/GA(2)LEN/EDF/ WAO guideline for the definition, classification, diagnosis and management of urticaria

Chronic urticaria and its impact on the quality of life of Nepalese patients

A prospective ten-year follow-up of patients with chronic urticaria

Does anti-IgE therapy help in asthma? Efficacy and controversies

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria

Pharmaceutical approval update

Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria

COVID-19 and biologics for psoriasis: a high-epidemic area experience-Bergamo

Psoriasis and COVID-19: a narrative review with treatment considerations

Rhinovirus and serum IgE are associated with acute asthma exacerbation severity in children

Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab

Review on COVID-19 etiopathogenesis, clinical presentation and treatment available with emphasis on ACE2

A novel coronavirus outbreak of global health concern

COVID-19 vasculitis and novel vasculitis mimics

Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy

Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during redzone declaration

Respiratory infections associated with anti-TNFalpha agents

Omalizumab updosing for better disease control in chronic spontaneous urticaria patients

A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis

What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2?

Anti-IgE monoclonal antibodies as potential treatment in COVID-19

COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children

Omalizumab and COVID-19 treatment: could it help?

The global impact of the COVID-19 pandemic on the management and course of chronic urticaria

COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases

Comorbidities and age are associated with persistent COVID-19 PCR positivity

Association of sex, age, and comorbidities with mortality in COVID-19 patients: a systematic review and meta-analysis

The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross-sectional, comparative study